title: [Comparative evaluation of biological availability and anti-arrhythmia effectiveness of Mexicard (mexiletine Polfa)].
abstract: In 16 healthy males bioavailability of Mexicord (Polfa) was studied, in comparison with mexiletine of foreign made. Bioavailability extent (EBA) of Mexicord was over 99% in comparison with a standard drug. Comparative study of antiarrhythmic activity and side effects was performed in 32 patients with frequent ventricular premalure beats and nearly in a half of them resistant to antiarrhythmic agents. Mexicord was effective in 47% of treated patients, and side effects (most often nausea) were observed in 28% of patients, but only in 1 case therapy withdrawal was necessary. Statistical study proved a lack of significant differences in antiarrhythmic effectiveness and side effects between Mexicord (Polfa) and a drug of foreign made.
authors: Z
authors: Z
authors: Sadowski
authors: D
authors: D
authors: Paczkowski
authors: M
authors: M
authors: Markiewicz
authors: E
authors: E
authors: Nartowicz
authors: P
authors: P
authors: Koliński
authors: M
authors: M
authors: Filipek
mesh_terms: D000328:Adult; D000368:Aged; D001682:Biological Availability; D005117:Cardiac Complexes, Premature / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D005260:Female; D005860:Germany, West; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008875:Middle Aged; D011044:Poland; D013997:Time Factors
chemical_list: D008801:Mexiletine
vernacular_title: Ocena porównawcza biodostepności i skuteczności antyarytmicznej Mexicordu (meksyletyny Polfa).